Scarica l'app Stockscreener
49.87
0.34%
0.17
Dopo l'orario di chiusura:
49.92
0.05
+0.10%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$49.70
Aprire:
$49.16
Volume 24 ore:
9.02M
Relative Volume:
0.78
Capitalizzazione di mercato:
$19.49B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-5.7125
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
+18.09%
1M Prestazione:
+15.98%
6M Prestazione:
+85.46%
1 anno Prestazione:
+47.85%
Intervallo 1D:
$48.29
$50.48
Intervallo di 1 settimana:
$41.97
$50.48
Portata 52W:
$22.28
$55.20
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
49.87 | 19.42B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.90 | 119.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.67 | 82.71B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
844.41 | 52.43B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
336.19 | 45.01B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
362.14 | 39.23B | 4.98B | 69.60M | 525.67M | 0.5198 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
BioNTech Says Moderna's New COVID Vax Infringes Its IP - Law360
Court Narrows Moderna Defenses in Arbutus Patent Dispute - TipRanks
Moderna (MRNA) Shows Mixed Options Sentiment Amid Modest Price D - GuruFocus
Moderna, Inc. SEC 10-K Report - TradingView
Arbutus Biopharma wins partial summary judgment on Moderna defenses; enablement dispute to go to jury - TradingView
Netflix, Klarna, Shopify, Palo Alto, Moderna: What brokers said this week - Proactive financial news
Moderna and Merck Advance mRNA Cancer Vaccine Trial in First-Line Lung Cancer: What Investors Should Watch - TipRanks
Moderna Faces Lawsuit From BioNTech Over Next-Generation COVID-19 Shot - Benzinga
Moderna (MRNA) Faces Legal Challenge Over COVID-19 Vaccine Paten - GuruFocus
FDA reverses course on Moderna mRNA flu vaccine, review initiated - Fox Business
GSK Can Tweak COVID Vaccine UPC Claim Against Moderna - Law360
RFK Jr.'s public health shakeups turning vaccine makers away - upi.com
BioNTech sues Moderna for patent infringement over COVID shots - Yahoo Finance
BioNTech Sues Moderna Over COVID-19 Vaccine Technology Patent - marketscreener.com
Moderna (MRNA) Faces Patent Lawsuit Over COVID-19 Vaccine - GuruFocus
GSA Capital Partners LLP Boosts Stock Position in Moderna, Inc. $MRNA - MarketBeat
Moderna faces COVID vaccine patent suit from BioNTech (MRNA) - Seeking Alpha
BioNTech Sues Moderna Over Illegal Use of COVID-19 Vaccine Technology - marketscreener.com
Barclays starts Moderna, Inc. (MRNA) neutral as biotech outlook improves - MSN
Moderna’s Q4 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Moderna jumps as FDA agrees to review its mRNA flu vaccine after earlier setback - Quiver Quantitative
BioNTech sues Moderna over alleged patent infringement involving a Covid vaccine - marketscreener.com
Moderna (NASDAQ:MRNA) Shares Up 7.1%Time to Buy? - MarketBeat
Key facts: Moderna shares rise on flu vaccine review; BioNTech sues Moderna; Patent case setback for Moderna - TradingView
BioNTech sues Moderna for patent infringement over COVID-19 shots - BNN Bloomberg
Moderna’s Covid Vaccine Targeted in New BioNTech Patent Suit (2) - Bloomberg Law News
Will vaccine regulatory uncertainty chill innovation? Pharma execs sound off. - Pharma Voice
Moderna Stock Jumps After FDA Reverses Course on Flu Shot - TradingView
First Look: Walmart beat, Meta trial, FDA eyes Moderna - GuruFocus
🎧 The Moderna Flu-Shot Drama - The Wall Street Journal
Moderna to Present at Upcoming Conferences in March 2026 - ACCESS Newswire
FDA agrees to review Moderna's mRNA flu vaccine after refusal-to-file - WEAR-tv
Thrivent Financial for Lutherans Has $345,000 Stake in Moderna, Inc. $MRNA - MarketBeat
FDA will review Moderna’s new flu shot after all - Morning Brew
Moderna’s new flu vaccine to undergo review by FDA | Health Watch - CBS News
Moderna says the FDA will consider its new flu shot after resolving a public dispute - Griffin Daily News
After Moderna Flu Vaccine, Is US FDA’s Accelerated Approval A Pathway Or A Pressure Valve? - Citeline News & Insights
Is Moderna Inc (MRNA) Set to Underperform? Analyzing the Factors Limiting Growth - GuruFocus
FDA Reverses Decision About Moderna Flu Vaccine - The Bulwark
🎧 The Moderna Flu Shot Drama - The Wall Street Journal
Stock Movers: eBay, Moderna, Vita Coco - Bloomberg
FDA’s abrupt flip-flop on Moderna’s mRNA flu shot highlights growing risks to drug-makers of investing in vaccines - The Conversation
Moderna Loses 2 Defenses In Patent Fight - GuruFocus
FDA reverses course, will review Moderna’s flu vaccine application - Honolulu Star-Advertiser
Market Today: Moderna rebounds; oil and gold jump - GuruFocus
3 Once-in-a-Decade Buying Opportunities - The Motley Fool
Moderna got a win from the FDA, but political headwinds remain a concern for vaccine makers - The Boston Globe
Moderna’s flu vaccine back in play as FDA shifts course on review - BioWorld MedTech
FDA Changes Mind, Will Review Moderna MRNA Flu Vaccine - Law360
F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine - The New York Times
FDA reverses course on Moderna flu shot - KNKX
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.89%
2.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):